Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing drugs to treat central nervous system (CNS) diseases and other disorders in the United States. Its lead product candidate, d-Methadone, is being developed as a rapidly acting, oral agent for the treatment of depression, neuropathic pain, and/or other potential CNS pathological conditions. The company is also developing LevoCap ER, an extended release, abuse deterrent, proprietary formulation of the opioid analgesic levorphanol for the treatment of pain; BuTab ER, a formulation of oral, modified release buprenorphine for chronic pain and opioid dependence; and MepiGel, a proprietary topical dosage form of the local anesthetic mepivacaine for the treatment of painful peripheral neuropathies, such as painful diabetic neuropathy, postherpetic neuralgia, and painful HIV-associated neuropathy. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in New York, New York.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
WebN/A
PhoneN/A
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees3
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable
Relmada Therapeutics (OTCMKTS:RLMD) Frequently Asked Questions
What is Relmada Therapeutics' stock symbol?
Relmada Therapeutics trades on the OTCMKTS under the ticker symbol "RLMD."
How were Relmada Therapeutics' earnings last quarter?
Relmada Therapeutics Inc (OTCMKTS:RLMD) announced its quarterly earnings data on Tuesday, November, 13th. The company reported ($0.27) earnings per share for the quarter. View Relmada Therapeutics' Earnings History.
When is Relmada Therapeutics' next earnings date?
Has Relmada Therapeutics been receiving favorable news coverage?
Media stories about RLMD stock have trended very negative on Thursday, InfoTrie Sentiment reports. The research group scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Relmada Therapeutics earned a news sentiment score of -3.2 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Relmada Therapeutics.
What other stocks do shareholders of Relmada Therapeutics own?
Who are Relmada Therapeutics' key executives?
Relmada Therapeutics' management team includes the folowing people:
- Dr. Sergio Traversa M.B.A., Pharm.D., PharmD, MBA, CEO, Interim CFO & Director (Age 59)
- Dr. Ottavio V. Vitolo M.D., Sr. VP, Head of R&D and Chief Medical Officer (Age 46)
- Mr. Michael D. Becker, Consultant (Age 50)
- Dr. Richard M. Mangano, Consultant (Age 69)
- Ms. Gina DiGuglielmo, VP & Head of Clinical Operations
How do I buy shares of Relmada Therapeutics?
Shares of RLMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Relmada Therapeutics' stock price today?
One share of RLMD stock can currently be purchased for approximately $23.10.
How big of a company is Relmada Therapeutics?
MarketBeat Community Rating for Relmada Therapeutics (OTCMKTS RLMD)
MarketBeat's community ratings are surveys of what our community members think about Relmada Therapeutics and other stocks. Vote "Outperform" if you believe RLMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RLMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
